A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Recruiting now

Conditions studied: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

In brief

The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate

Key facts

Study ID

NCT06681623

Run by

Neurology Center of New England P.C.

People needed

20

Starts

2024-08-13

Expected to finish

2027-09-30

Last updated by the study team

2024-11-18

Who can join

Age: 55 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent
• Aged 55-80 years old
• Diagnosis of RMS according to the 2017 Revised McDonald criteria
• Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label

You may not qualify if…

• Active participation in an interventional clinical trial for MS
• Received initial dose of ublituximab more than 6 months prior to study entry
• History of life-threatening infusion reaction on any anti-CD20 therapy
• Evidence of clinically significant chronic or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment, or any history of recurrent infection within 6-12 months prior to initiation of ublituximab

Where it is running

• Neurology Center of New England P.C. — Foxborough, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.